Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01061606 · OUTCOME

Duration of Response, Defined for All Evaluable Patients Who Have Achieved an Objective Response as the Date at Which the Patient's Objective Status is First Noted to be Either a CR or PR to the Date Progression is Documented

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus · Source last updated 2016-11-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 3 years

What was measured

Median duration of response and the confidence interval for the median duration will be computed.

Analysis population: The study concluded terminated early and patients were not followed.

Groups in this outcome

Treatment (Temsirolimus)

Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Temsirolimus)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Median duration of response and the confidence interval for the median duration will be computed.
groups
  1. description
    Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV
    id
    OG000
    title
    Treatment (Temsirolimus)
population Description
The study concluded terminated early and patients were not followed.
reporting Status
POSTED
time Frame
Up to 3 years
title
Duration of Response, Defined for All Evaluable Patients Who Have Achieved an Objective Response as the Date at Which the Patient's Objective Status is First Noted to be Either a CR or PR to the Date Progression is Documented
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice